ArticleAmerican journal of translational research2025
PD-1 inhibitor therapy combined with argon-helium cryoablation is effective against non-small cell lung cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives.Immunotherapy · 2026Review
- Integrating cryoablation with immunotherapy in non-small cell lung cancer: mechanisms, clinical evidence, and translational barriers.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of programmed death-1 (PD-1) inhibitor therapy combined with argon-helium cryoablation in patients with non-small cell lung cancer (NSCLC).
methodsA total of 108 NSCLC patients were enrolled. The control group included 52 patients who received PD-1 inhibitor monotherapy, while 56 patients received combination therapy with PD-1 inhibitors and argon-helium cryoablation (research group). Treatment efficacy, incidence of adverse events, serum tumor marker levels (carcinoembryonic antigen, cytokeratin fragment 19), and humoral immune function (immunoglobulin (Ig) G, IgM, and IgA), and quality of life (as measured by the Karnofsky Performance Status [KPS]) were compared between the two groups. Independent predictors of treatment response were identified through univariate analysis followed by binary logistic regression. A nomogram was subsequently developed to visualize the risk of treatment failure.
resultsAlthough the incidence of adverse events was comparable between groups (P>0.05), the research group demonstrated a significantly higher overall response rate (P<0.05). Post-treatment analyses revealed significant reductions in serum tumor markers and increases in immunoglobulin levels and KPS scores in the research group (all P<0.05). Logistic regression identified age ≥55 years (odds ratio [OR]: 2.427) and tumor diameter ≥6.00 cm (OR: 3.394) as independent predictors of poor treatment response (all P<0.05). The nomogram model exhibited moderate discriminative ability, though calibration suggested a tendency to overestimate response rates in the low-risk subgroup.
conclusionPD-1 inhibitor therapy combined with argon-helium cryoablation offers a promising and effective treatment strategy for patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.